SSRIs for Premature Ejaculation: Why Sertraline and Citalopram Are Both Good Answers to One of Men’s Most Common Complaints
Introduction
Premature ejaculation is the most common male sexual dysfunction worldwide — affecting an estimated 20–30% of sexually active men across all age groups and cultures. Yet despite its extraordinary prevalence, it remains one of the most undertreated and least openly discussed conditions in men’s health. Shame, embarrassment, and the persistent misperception that PE is a psychological weakness rather than a neurobiological condition prevent most affected men from ever seeking medical help.
PE is associated with personal distress, relationship difficulties, and reduced quality of life for both partners. The consequences extend beyond the bedroom — anxiety, avoidance of intimacy, relationship deterioration, and depression are documented comorbidities that compound the condition’s initial impact.
The pharmacological revolution in PE treatment — driven by the serendipitous discovery that SSRI antidepressants delay ejaculation as a side effect — has transformed the clinical landscape. The 2008 Urology Journal RCT by Akgül, Karakan, Ayyıldız and Germiyanoğlu directly addressed a practical clinical question: when an Iranian or Turkish urologist prescribes an SSRI for PE, should they choose sertraline or citalopram? Their answer — both work equally well — has been confirmed by subsequent meta-analyses and systematic reviews, and continues to guide SSRI selection in clinical practice.
Defining Premature Ejaculation: From Debate to Consensus
The ISSM Definition
For decades, PE lacked a universally accepted definition — a problem that made research comparison impossible. The International Society for Sexual Medicine (ISSM) 2014 definition brought consensus:
Lifelong PE is defined as: a male sexual dysfunction characterized by ejaculation that always or nearly always occurs prior to or within approximately 1 minute of vaginal penetration; inability to delay ejaculation on all or nearly all vaginal penetrations; and negative personal consequences such as distress, bother, frustration, and/or avoidance of sexual intimacy.
Acquired PE uses the same criteria but specifically refers to onset after a period of normal ejaculatory function.
IELT: The Objective Measurement Tool
The intravaginal ejaculatory latency time (IELT) — measured from vaginal penetration to ejaculation using a stopwatch — provides an objective, quantifiable endpoint for clinical trials. In the four-SSRI comparison trial, mean IELT before treatment across groups ranged from 69–90 seconds, significantly below the population median of approximately 5.4 minutes.
The Akgül et al. 2008 trial used the Index of Premature Ejaculation (IPE) questionnaire — a validated patient-reported outcome measure covering ejaculatory control, sexual satisfaction, and distress — as their primary endpoint, providing a patient-centered complement to stopwatch IELT measurement.
The Serotonin Connection: Why SSRIs Delay Ejaculation
Neurobiological Basis
Ejaculation is controlled by a spinal ejaculation generator in the lumbar spinal cord (the spinal ejaculatory generator, SEG), modulated by descending serotonergic pathways from the brainstem. Serotonin (5-HT) exerts an inhibitory effect on ejaculation through 5-HT₂C receptors — activation of these receptors delays ejaculation, while 5-HT₁A receptor activation shortens it.
Men with lifelong PE have hypersensitive penile sensory pathways, reduced serotonergic inhibitory tone, and a constitutionally low ejaculatory threshold. Pharmacologically increasing synaptic serotonin — as all SSRIs do, by blocking the serotonin reuptake transporter — raises this threshold, delaying the ejaculatory reflex.
The discovery of SSRIs’ ejaculation-delaying properties was serendipitous: patients being treated for depression reported significantly prolonged time to ejaculation as a side effect. Urologists recognized this as therapeutic potential and began systematically studying SSRIs for PE treatment — first paroxetine (the most potent ejaculation delayer), then sertraline, fluoxetine, citalopram, and escitalopram.
Sertraline vs. Citalopram: The Head-to-Head Evidence
The Akgül 2008 Urology Journal RCT
Of 101 married men with PE, 80 were eligible and consented to participate in this randomized controlled trial. Erectile dysfunction and administration of drugs for the treatment of PE were the exclusion criteria. The patients were evaluated using the Index of Premature Ejaculation (IPE) questionnaire and were randomly assigned to sertraline (group 1) or citalopram (group 2). They received one of these drugs for 8 weeks and then were re-evaluated by the IPE.
The authors reported a statistically significant increase in the results of the IPE questionnaire in both the citalopram and sertraline groups, without a significant difference in efficacy between the two treatments. No serious adverse effects were detected in any of the patients and both drugs were well tolerated.
The study’s key clinical message: when choosing between sertraline and citalopram for PE, clinical factors — availability, cost, tolerability profile, and patient preference — rather than efficacy differences should guide the decision.
Pharmacological Profiles Compared
| Parameter | Sertraline | Citalopram |
| Standard PE dose | 50 mg daily or on-demand | 20 mg daily or on-demand |
| Half-life | ~26 hours | ~35 hours |
| Time to peak plasma (Tmax) | ~6–8 hours | ~4 hours |
| Selectivity | High SERT selectivity | Highest SERT selectivity of all SSRIs |
| Cardiac effects | Minimal | QTc prolongation concern at high doses |
| Drug interactions | Moderate CYP2D6 inhibitor | Minimal CYP inhibition |
| Generic availability | Widely available; low cost | Widely available; low cost |
| On-demand suitability | Yes (4–6 h before intercourse) | Yes (4 h before intercourse) |
With considering the Tmax of these drugs, it seems that on-demand use of citalopram and sertraline may be more effective and safe in the treatment of PE than other SSRIs. Citalopram’s faster time to peak concentration makes it theoretically slightly better suited to on-demand dosing — a clinically relevant consideration for men who prefer situational rather than daily treatment.
The Broader SSRI Evidence Base for PE
The Four-SSRI Comparison Trial
A randomized clinical trial enrolled 480 patients with PE in four groups receiving sertraline 50mg, fluoxetine 20mg, paroxetine 20mg, and citalopram 20mg every 12 hours daily. Mean IELT before, 4 and 8 weeks after treatment were: sertraline 69.4±54.3, 353.5±190.4, 376.3±143.5 seconds; fluoxetine 75.5±64.3, 255.4±168.2, 314.8±190.4 seconds; paroxetine 71.5±69.1, 320.7±198.3, 379.9±154.3 seconds; citalopram 90.39±79.3, 279.9±192.1, 282.5±171.1 seconds. The ejaculation time significantly increased in all groups (P < 0.05), but there was no significant difference between the groups (P = 0.75).
These results represent a 3–5 fold increase in IELT across all SSRIs — a dramatic pharmacological effect that translates directly into meaningful clinical improvement. The absence of significant between-group differences confirms what the Akgül 2008 study found for sertraline versus citalopram specifically: SSRI class effects on ejaculation are shared across agents.
Daily vs. On-Demand Dosing
Mean IELT before, 4 and 8 weeks after treatment were: on-demand group 101.62±65.44s, 208.75±128.02s and 265.87±145.70s; daily use group 102.50±81.22s, 276.87±181.08s and 353.75±176.45s. The ejaculation time increased significantly in both groups (P<0.05). However, increase in ejaculation time in daily use was significantly higher than on-demand at 4 weeks (P=0.036) and 8 weeks (P=0.009).
Daily dosing produces superior IELT prolongation — but at the cost of continuous drug exposure and side effects. On-demand dosing offers less efficacy but better tolerability, no daily pill burden, and no systemic side effects on non-intercourse days. For men with infrequent sexual activity or those concerned about systemic SSRI effects, on-demand dosing represents a meaningful clinical compromise.
Dapoxetine: The Purpose-Designed Solution
Dapoxetine — a short-acting SSRI with a half-life of approximately 1.5 hours, specifically developed for on-demand PE treatment — was designed to address the SSRI’s main limitation: conventional SSRIs were developed for psychiatric disorders, not PE, and carry systemic serotonergic effects even on non-intercourse days.
Although dapoxetine has been introduced as the drug of choice for PE treatment, in clinical practice drugs are chosen based on availability in the country. In Iran, other SSRIs are available. Although dapoxetine is also found in Iran, due to its cost and limited distribution, drugs such as citalopram, sertraline, and paroxetine are commonly used.
This practical reality — that dapoxetine’s superior pharmacokinetic profile for on-demand dosing is offset by cost and availability barriers in many countries — explains why the Akgül 2008 comparison of conventional SSRIs remains clinically relevant a decade and a half after publication.
Side Effects: What Men Need to Know
Common SSRI Side Effects Relevant to PE Treatment
Both sertraline and citalopram are generally well tolerated at the doses used for PE — which are typically lower than doses used for depression. The main side effects to discuss with patients:
- Nausea: most common; usually transient (resolves within 1–2 weeks of daily dosing)
- Headache: common in first weeks; typically self-limiting
- Diarrhea: more common with sertraline than other SSRIs
- Delayed orgasm/anorgasmia: the therapeutic effect itself can overshoot — some patients experience difficulty reaching orgasm at all, which is undesirable
- Reduced libido: less common at PE doses than antidepressant doses
- Sexual partner effects: partners of men treated for PE sometimes report reduced satisfaction if the partner perceives sexual encounters as lasting “too long”
Cardiac considerations for citalopram: at doses above 40 mg/day, citalopram is associated with QTc interval prolongation — a concern that led to FDA dose restrictions for depression treatment. At the 20 mg doses used for PE, this risk is negligible, but patients with pre-existing cardiac conditions or those taking other QTc-prolonging drugs warrant electrocardiographic assessment before citalopram use.
Conclusion
The Akgül 2008 Urology Journal RCT — “Comparison of Sertraline and Citalopram for Treatment of Premature Ejaculation” — addressed a simple but clinically important question with methodological rigor: when both drugs work through the same mechanism and are available in your market, does it matter which one you prescribe? The answer — no significant difference in efficacy, both safe and well tolerated — remains supported by subsequent larger trials and systematic reviews, and continues to guide SSRI selection in Turkey, Iran, and the broader Middle Eastern and South Asian context where both sertraline and citalopram are widely available generics.
SSRI treatment probably results in an improvement in PE-related symptoms defined as a rating of ‘better’ or ‘much better’ using the CGIC questionnaire compared to placebo (risk ratio 1.92; 95% CI, 1.66–2.23; moderate certainty of evidence).
Your next steps if you or your patient has premature ejaculation:
- Seek medical evaluation without embarrassment — PE is a neurobiological condition, not a character flaw; urologists and sexual medicine specialists treat it routinely and effectively
- Understand that both daily and on-demand SSRI dosing are evidence-supported options; discuss your sexual frequency and lifestyle preferences with your prescribing physician to determine which regimen suits you best
- Ask specifically about the IPE (Index of Premature Ejaculation) or PEDT (Premature Ejaculation Diagnostic Tool) questionnaire — validated outcome measures allow objective tracking of treatment response rather than subjective impression
- Combine pharmacological treatment with behavioral techniques (start-stop method, squeeze technique, pelvic floor exercises) — combination therapy typically outperforms either approach alone
- If sertraline or citalopram is prescribed, allow 4–8 weeks before assessing full efficacy — the ejaculation-delaying effect builds over weeks of treatment; do not abandon treatment after a single trial
- Discuss the possibility of on-demand dosing with your physician if you prefer not to take daily medication — the 4–6 hour Tmax window for sertraline and ~4 hour window for citalopram makes pre-intercourse dosing pharmacologically rational and clinically validated